该文报道2例接受贝林妥欧单抗桥接治疗的急性B淋巴细胞白血病（B-cell acute lymphoblastic leukemia, B-ALL）合并侵袭性真菌病（invasive fungal disease, IFD）患儿。病例1为4个月女婴，化疗期间反复高热伴肢体肌力下降，血培养及外周血、支气管肺泡灌洗液、脑脊液二代测序（next-generation sequencing, NGS）均阴性，但胸部CT和头颅MRI可见明显感染灶。病例2为2岁男性患儿，化疗期间反复高热伴多部位炎性包块，外周血及包块脓液NGS均检出热带念珠菌，血培养及影像学检查未见明显异常。2例患儿经抗真菌和贝林妥欧单抗治疗后症状、体征及影像学表现明显好转，并且B-ALL处于持续缓解状态。该报道表明，B-ALL合并IFD患儿接受贝林妥欧单抗桥接治疗可在免疫抑制合并严重真菌感染时重建免疫系统并控制原发病。
Abstract
This article reports two cases of children with B-cell acute lymphoblastic leukemia (B-ALL) complicated by invasive fungal disease (IFD) who received bridging treatment using blinatumomab. Case 1 was a 4-month-old female infant who experienced recurrent high fever and limb weakness during chemotherapy. Blood culture was negative, and next-generation sequencing (NGS) of peripheral blood, bronchoalveolar lavage fluid, and cerebrospinal fluid were all negative. Chest CT and cranial MRI revealed obvious infection foci. Case 2 was a 2-year-old male patient who experienced recurrent high fever with multiple inflammatory masses during chemotherapy. Candida tropicalis was detected in peripheral blood and abscess fluid using NGS, while blood culture and imaging examinations showed no obvious abnormalities. After antifungal and blinatumomab therapy, both cases showed significant improvement in symptoms, signs, and imaging, and B-ALL remained in continuous remission. The report indicates that bridging treatment with blinatumomab in children with B-ALL complicated by IFD can rebuild the immune system and control the underlying disease in the presence of immunosuppression and severe fungal infection.
关键词
急性B淋巴细胞白血病 /
贝林妥欧单抗 /
侵袭性真菌病 /
儿童
Key words
B-cell acute lymphoblastic leukemia /
Blinatumomab /
Invasive fungal disease /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia[J]. J Clin Med, 2021, 10(9): 1926. PMID: 33946897. PMCID: PMC8124693. DOI: 10.3390/jcm10091926.
2 中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10): 754-763. PMID: 32987477. DOI: 10.3760/cma.j.cn112138-20200627-00624.
3 Goebeler ME, Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy[J]. Leuk Lymphoma, 2016, 57(5): 1021-1032. PMID: 27050240. DOI: 10.3109/10428194.2016.1161185.
4 Pawinska-Wasikowska K, Wieczorek A, Balwierz W, et al. Blinatumomab as a bridge therapy for hematopoietic stem cell transplantation in pediatric refractory/relapsed acute lymphoblastic leukemia[J]. Cancers (Basel), 2022, 14(2): 458. PMID: 35053619. PMCID: PMC8773605. DOI: 10.3390/cancers14020458.
5 Ampatzidou M, Kattamis A, Baka M, et al. Insights from the Greek experience of the use of blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients[J]. Neoplasma, 2020, 67(6): 1424-1430. PMID: 32701357. DOI: 10.4149/neo_2020_200128N93.
6 Kantarjian H, Stein A, G?kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9): 836-847. PMID: 28249141. PMCID: PMC5881572. DOI: 10.1056/NEJMoa1609783.
7 Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial[J]. JAMA, 2021, 325(9): 833-842. PMID: 33651090. PMCID: PMC7926290. DOI: 10.1001/jama.2021.0669.
8 Verma A, Wüthrich M, Deepe G, et al. Adaptive immunity to fungi[J]. Cold Spring Harb Perspect Med, 2014, 5(3): a019612. PMID: 25377140. PMCID: PMC4355251. DOI: 10.1101/cshperspect.a019612.
9 Halford Z, Coalter C, Gresham V, et al. A systematic review of blinatumomab in the treatment of acute lymphoblastic leukemia: engaging an old problem with new solutions[J]. Ann Pharmacother, 2021, 55(10): 1236-1253. PMID: 33435716. DOI: 10.1177/1060028020988411.
10 Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial[J]. JAMA, 2021, 325(9): 843-854. PMID: 33651091. PMCID: PMC7926287. DOI: 10.1001/jama.2021.0987.
11 Brown P, Pieters R, Biondi A. How I treat infant leukemia[J]. Blood, 2019, 133(3): 205-214. PMID: 30459160. DOI: 10.1182/blood-2018-04-785980.
12 Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis, 2019, 19(12): e405-e421. PMID: 31699664. PMCID: PMC8559573. DOI: 10.1016/S1473-3099(19)30312-3.
13 Yeoh DK, Haeusler GM, McMullan BJ, et al. Antifungal use in children with acute leukaemia: state of current evidence and directions for future research[J]. J Antimicrob Chemother, 2022, 77(6): 1508-1524. PMID: 35301533. DOI: 10.1093/jac/dkac060.
14 Yeoh DK, Blyth CC, Kotecha RS. Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease[J]. Br J Haematol, 2022, 198(5): 887-892. PMID: 35727917. PMCID: PMC9539952. DOI: 10.1111/bjh.18314.
15 Contreras CF, Higham CS, Behnert A, et al. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2021, 68(1): e28718. PMID: 33098744. PMCID: PMC7688575. DOI: 10.1002/pbc.28718.
PDF(783 KB)
